We Are Changing The World by Making The Best Vaccines, Pharmaceuticals, and Nutraceuticals Better.
About Mountain Valley MD
MVMD is on a journey with the goal to positively impact the health and wellness of every human, husbandry and companion animal on the planet. We’re a group of believers, inventors and explorers who are relentless in the pursuit of a better world. We trust in the limitless power of science, fueled by human empathy, all with the focus to free millions of people from the tragedy of preventable disease.
Corporate Presentation
CSE: MVMD
OTCQB: MVMDF
FRA: 20MP
Recent News Releases
Current Pipeline
Management
Dennis Hancock - President & CEO, Mountain Valley MD – Board of Directors
Dennis Hancock is a senior sales and marketing executive with over 25 years of experience spanning automotive, pharmaceutical, tech, telco, retail and financial services sectors. Initially providing consulting services to Mountain Valley MD in 2018, Dennis transitioned to assume the President & CEO position in early 2019 to lead the Company’s go-public strategy and develop the business strategy to pursue broad health and wellness opportunities approach across human, animal and plant health applications. Dennis spent more than 12 years in a leadership role at one of North America’s leading performance improvement and Loyalty providers, Maritz, who works with 70% of the world’s Super 50 companies. Previously, Dennis led publicly traded ZENN Motor Company as the Vice President of Sales and Marketing. As a senior officer at ZMC, Dennis drove the establishment of ZENN – (Zero Emission, No Noise) as one of the most recognized “green tech” brands in North America. Dennis has several start-ups established, including PerformanceSPARK, an agency that works with leading organizations to identify and deliver on the key elements necessary to drive measurable performance growth, and co-founder of CrowdSeating Inc., an innovative social concert platform.
Aaron Triplett - CFO, Mountain Valley MD
Aaron Triplett is a Chartered Professional Accountant (CPA, CA), and has accumulated over 15 years experience in the field of financial management and accounting, specializing in forecasting, compliance and risk management, and the development and monitoring of control systems. Most recently, Mr. Triplett served as CFO of Grande West Transportation Group Inc. (TSXV: BUS), a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States. Aaron was instrumental in the Company’s financial growth initiatives, securing a $20 million and $5 million revolving credit facility with major Canadian banks. Prior to that, Mr. Triplett served as the CFO of Angkor Resources Corp. (TSXV: ANK), a mineral exploration company with operations in Cambodia. Mr. Triplett’s work experience also includes audit and assurance manager for a mid size public accounting firm.
Mike Farber - Director of Life Sciences
Mike Farber is MVMD’s lead inventor and principal scientist. Mike’s father, Harold Cyril Farber, had polio and that despite all the tragedies of this story, it was the core of Mike’s personal mission to work on technology that truly has the potential to eradicate polio and it is foundational to all of the transformational work we are doing at Mountain Valley MD. Utilizing his background in biochemistry, Mike began his career in research and development doing polymer research for container-packaging company Consolidated Bathurst in Montreal. Farber has focused his attention primarily in the area of novel delivery systems for both nutraceuticals and pharmaceuticals. This work over the last two decades has led to his authoring over a hundred patents. The main focus of this work has been to improve the bioavailability of compounds to enhance effectiveness, efficiency and convenience. Mike’s most important current developments include the patented desiccated liposomal rapid dissolve delivery system, macrocyclic lactone drug solubilization and novel dose sparing adjuvant.
Pharma/ Scientific Advisor Board
Sid Senroy
Mr. Senroy is a seasoned pharmaceutical executive with an MBA from Pepperdine University with expertise in helping companies pass compliance assessments, develop robust quality systems and prepare for U.S. Food and Drug Administration reviews and inspections. Over the past two decades, Mr. Senroy has successfully led several global Quality and Compliance business units as an executive or senior consultant, leading to the approval of key blockbuster drugs with cumulative sales exceeding $30 billion annually over the last 10 years. Mr. Senroy’s ability to form cross-functional alliances for improvement and growth, in addition to a sensitivity to cultural nuances, has helped him succeed on a global scale. He has worked extensively throughout North America, Europe, Asia and South America. Mr. Senroy works with the leadership team on pharmaceutical licensing strategy, facilitation of strategic introductions to key pharmaceutical partners and supports the development of the Company’s overall business development plan.
Azhar Rana, MD
Azhar Rana, MD, is the President of Integrated Medhealth Communication (IMC) North America and is a trained general medicine practitioner with a clinical background and has held a number of senior medical positions at Bristol-Myers Squibb, Novo Nordisk and most recently at AstraZeneca.
Dr. John Clements, PHD
Dr. John Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine. With over 35 years of experience in vaccine, immunology and infectious diseases research and development, Dr. Clements brings invaluable expertise and advisory capacity to help advance Mountain Valley MD’s ongoing Quicksome™ sublingual polio vaccine development activities. Dr. Clements’ distinguished scientific career has focused on developing and evaluating vaccines for a wide range of infectious diseases globally (including diarrheal diseases, Polio and HIV), including involvement in academia, research and
development, governmental and vaccine advisory boards and professional journals. Dr. Clements has published more than 150 peer-reviewed papers, has 14 issued patents, and has been involved in numerous vaccine clinical trials. Dr. Clements has worked with leading vaccine focused organizations such as the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and the United States Military.
Dr. Michel Rondeau
Michel Rondeau, Doctor of Veterinary Medicine, oversees MVMD’s husbandry and companion animal studies, while driving global pharmaceutical animal applications as part of the ongoing business commercialization of MVMD’s technology. Dr. Rondeau has extensive experience in veterinary research having worked with numerous pharmaceutical companies in animal drug field trials and is credited with co-inventing a global award winning sprayable vaccination device that was acquired by Rhone Poulenc. Dr. Rondeau has completed an extensive range of research and development projects across a diverse range of husbandry
animals including porcine industrial medicine across preventative and curative medicine, nutrition and animal health products and automated feed systems.